Last reviewed · How we verify

Tindal (ACETOPHENAZINE)

Merck & Co. · FDA-approved approved Small molecule Quality 26/100

Tindal (acetophenazine) is a small molecule drug originally developed by Schering and currently owned by the same company. It targets the D(2) dopamine receptor and is used to treat psychotic disorders. Tindal was FDA-approved in 1961 and is now off-patent, meaning there are no active Orange Book patents. As a result, there are currently no generic manufacturers of the drug. Despite its off-patent status, key safety considerations for Tindal are not well-documented due to a lack of available information on its pharmacokinetics.

At a glance

Generic nameACETOPHENAZINE
SponsorMerck & Co.
Drug classacetophenazine
TargetD(2) dopamine receptor
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved
First approval1961

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions